Drugs cost money. Pharmacoeconomics studies whether they are worth it. The field compares the costs and outcomes of different treatments, helping payers, hospitals, and policymakers decide which drugs to cover and how to use them. It is not just about price. It is about value: how much health benefit a drug produces for the money spent.

Several methods are used. Cost-effectiveness analysis compares the cost per unit of health outcome, often expressed as cost per quality-adjusted life year, or QALY. Cost-benefit analysis assigns a monetary value to outcomes. Cost-minimization analysis compares drugs with identical outcomes and picks the cheapest. Budget impact analysis estimates how much a new drug will cost a health plan overall. These methods inform formulary decisions, reimbursement policies, and clinical guidelines. They are also controversial. Assigning a dollar value to a year of healthy life raises ethical questions, and different countries use different thresholds.

Key concepts:

• Cost-effectiveness. Cost per unit of health outcome, often per QALY.
• QALY. A measure combining length and quality of life.
• Budget impact. Total cost to a health plan.
• Cost-benefit. Comparing costs and benefits in monetary terms.
• Cost-minimization. Choosing the cheapest among equivalent options.

Pharmacoeconomic data are increasingly required by payers before they agree to cover expensive new drugs.